New Zealand markets close in 4 hours 4 minutes
  • NZX 50

    11,600.11
    -31.49 (-0.27%)
     
  • NZD/USD

    0.6324
    +0.0001 (+0.01%)
     
  • NZD/EUR

    0.6038
    +0.0020 (+0.33%)
     
  • ALL ORDS

    7,432.90
    -54.80 (-0.73%)
     
  • ASX 200

    7,235.60
    -55.70 (-0.76%)
     
  • OIL

    74.44
    +0.19 (+0.26%)
     
  • GOLD

    1,782.90
    +0.50 (+0.03%)
     
  • NASDAQ

    11,549.69
    -237.11 (-2.01%)
     
  • FTSE

    7,521.39
    -46.15 (-0.61%)
     
  • Dow Jones

    33,596.34
    -350.76 (-1.03%)
     
  • DAX

    14,343.19
    -104.42 (-0.72%)
     
  • Hang Seng

    19,441.18
    -77.11 (-0.40%)
     
  • NIKKEI 225

    27,885.87
    +65.47 (+0.24%)
     
  • NZD/JPY

    86.5280
    +0.1390 (+0.16%)
     

Hugel Aesthetics to Present Data from Phase 3 Clinical Trial At 2022 American Society of Dermatologic Surgery Annual Meeting

Results demonstrate that LetibotulinumtoxinA significantly improved the negative psychological burden associated with glabellar lines

NEWPORT BEACH, Calif., October 05, 2022--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that the company will have an oral presentation at the American Society for Dermatologic Surgery (ASDS) annual meeting (Oct. 6-10, 2022 in Denver, CO) highlighting data from its phase 3 clinical trial, BLESS III, assessing the efficacy of letibotulinumtoxinA in improving the psychosocial health-related quality of life (QoL) of subjects with moderate to severe glabellar lines.

"Hyperfunctional glabellar frown lines can transmit facial miscues that adversely affect emotional communication and facial attractiveness, increase perceptions of age, and diminish self-esteem. The BLESS III study included a comprehensive assessment of letibotulinumtoxinA’s efficacy on this important aspect of glabellar lines using multiple measures of psychologic impact," said Sue Ellen Cox, M.D., BLESS III investigator and lead author.

BLESS III (NCT03985982) was a prospective, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial (N=355) evaluating the efficacy and safety of letibotulinumtoxinA in the treatment of glabellar lines.1 A key secondary endpoint included change from baseline to Week 4 in psychological impact as measured on the validated Modified Skindex-16 Glabellar Lines QoL Scale, the FACE-Q Appraisal of Lines Between Eyebrows Scale, and the FACE-Q Age Appraisal Visual Analog Scale (VAS). Results from these measures and assessments of subject satisfaction with treatment will be presented at ASDS.

Jim Hartman, President and COO commented, "We look forward to sharing our analysis of the efficacy of letibotulinumtoxinA in mitigating the negative psychological burden associated with glabellar lines and its promotion of subject satisfaction with treatment outcome."

About Hugel Aesthetics

Hugel Aesthetics is a growth-focused joint venture between aesthetic marketing leading partners, Hugel, Inc and Croma-Pharma GmbH, focused on commercializing a synergistic aesthetic portfolio in the United States, Canada, and Australia.

The Hugel Aesthetics application for letibotulinumtoxinA for the treatment of glabellar lines is currently under review by the U.S. FDA.

Hugel Aesthetics is dedicated to making aesthetics more attainable for all. For more information, visit: www.hugel-aesthetics.com

1 Mueller et al. Aesthet Surg J 2022;42:677-688.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005589/en/

Contacts

Kayleigh Adam, Alison Brod Marketing Communications, kayleigh@abmc-us.com